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  Abstract 
    Objectives    .   Sexual dysfunction (SD) is a frequently reported side-effect of antidepressant treatment, particularly of selective 
serotonin reuptake inhibitors (SSRIs). In the multicentre clinical and pharmacogenetic GENDEP study (Genome-based 
Therapeutic Drugs for Depression), the effect of the serotonin transporter gene promoter polymorphism   5-HTTLPR   on 
sexual function was investigated during treatment with escitalopram (SSRI) and nortriptyline (tricyclic antidepressant). 
  Methods.   A total of 494 subjects with an episode of DSM-IV major depression were randomly assigned to treatment with 
escitalopram or nortriptyline. Over 12 weeks, depressive symptoms and SD were measured weekly with the Montgomery  –
  Asberg Depression Rating Scale, the Antidepressant Side-Effect Checklist, the UKU Side Effect Rating Scale, and the 
Sexual Functioning Questionnaire.   Results    .   The incidence of reported SD after 12 weeks of treatment was relatively low, 
and did not differ signiﬁ  cantly between antidepressants (14.9% escitalopram, 19.7% nortriptyline). There was no signiﬁ  cant 
interaction between the   5-HTTLPR   and antidepressant on SD. Improvement in depressive symptoms and younger age 
were both associated with lower SD. The effect of age on SD may have been moderated by the   5-HTTLPR.     Conclusions.       
In GENDEP, rates of reported SD during treatment were lower than those described in previous reports. There was no 
apparent effect of the   5-HTTLPR   on the observed decline in SD.   
    Key words:     Sexual dysfunction    ,    5-HTTLPR    ,    selective serotonin uptake inhibitors    ,    escitalopram    ,    nortriptyline     
    Introduction 
  Patients who receive antidepressants frequently 
report sexual dysfunction (SD), which may affect all 
phases of the sexual response cycle, i.e. desire, arousal, 
and orgasm. Estimates of medication-induced SD 
vary widely. Rates of between 10 and 90% have been 
reported, with higher rates for antidepressants which 
act on the serotonergic system (Werneke et al. 2006; 
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In a study of the treatment of premature ejaculation, 
long allele homozygotes showed a better SSRI treat-
ment response than short allele carriers (Safarinejad 
2010a).  
  Pharmacologically, SSRIs reduce the binding of 
serotonin to the serotonin transporter   –   a protein 
responsible for the transport of serotonin from the 
synaptic cleft into presynaptic serotonergic neurons   –   
thereby increasing the concentration of synaptic 
serotonin (5-HT) and facilitating the modulation of 
post-synaptic receptors (Stahl 1998). This SSRI 
effect may additionally decrease the concentrations 
of dopamine and noradrenaline in the mesolimbic 
system by activating serotonin 5-HT  2   receptors 
(Meltzer et al. 1979; Baldessarini and Marsh 1990; 
Done and Sharp 1992). Dopamine release within the 
mesolimbic system has been implicated as a major 
mechanism in sexual function (Bitran et al. 1988; 
Segraves 1989; Hull et al. 1999). Noradrenaline 
regulates sexual arousal (Lee and Pfaff 2008) and 
bup  ropion, a dopamine and noradrenaline reuptake 
in  hibitor, has been reported to decrease SSRI-in-
duced SD (Zisook et al. 2006; Safarinejad 2010b,c). 
However, the mechanisms through which SSRIs 
cause SD remain poorly understood (Segraves 2007; 
Perlis et al. 2009). SSRIs are currently the most 
commonly prescribed antidepressants. They have 
been reported to be highly effective in the treatment 
of depression and to cause fewer severe side effects 
than TCAs (Degner et al. 2004; Grohmann et al. 
1999). It is therefore important to elucidate the 
association between SSRIs and SD. 
  The aim of the present study was to assess SD rates 
during treatment with escitalopram and nortriptyline, 
and to determine the possible inﬂ  uence of   5-HTTLPR   
genotype on sexual function. The study was conducted 
within the context of a large European Commission 
funded multicentre study (Genome-based Therapeutic 
Drugs for Depression   –   GENDEP). Given previous 
ﬁ   ndings of an association between   5-HTTLPR   
genotype, SD, and treatment response during anti-
depressant treatment, we hypothesised that carriers 
of the   5-HTTLPR   long allele would experience a 
higher degree of SD during SSRI treatment than 
either short allele homozygotes or patients receiving 
TCAs.     
  Methods   
  Study design and sample 
  The GENDEP project is a multicentre pharmacoge-
netic study designed to compare the clinical and 
genetic determinants of therapeutic response to two 
antidepressants with contrasting primary modes 
of action   –   nortriptyline and escitalopram (http://
Serretti and Chiesa 2009; Williams et al. 2010). SD 
rates of around 40% have been reported for the 
selective serotonin reuptake inhibitor (SSRI) escit-
alopram (Clayton et al. 2006b, 2007), although 
lower rates were reported in a review published in 
2004 (Hirschfeld and Vornik 2004). Only one previ-
ous report has compared rates of SD during treat-
ment with tricyclics and SSRIs. This retrospective 
study included a small male sample and compared 
SD rates during treatment with ﬁ  ve tricyclic antide-
pressants (including nortriptyline) and three SSRIs 
(not including escitalopram). A higher rate of treat-
ment-associated SD was observed during treatment 
with SSRIs (Hsu and Shen 1995). Research suggests 
that SSRIs cause dysfunction in all phases of the 
sexual response cycle, predominantly in the phases 
of desire and orgasm in males and arousal in females 
(Clayton et al. 2006a; Corona et al. 2009; Serretti 
and Chiesa 2009). TCAs have been found to have 
particular effects on desire and orgasm, although 
they may also affect other phases of the sexual 
cycle since they modify several neurotransmitters 
(Werneke et al. 2006). SD is known to decrease 
compliance with antidepressant treatment, and 
effective strategies for its management are therefore 
essential (Rothschild 2000; Montejo et al. 2001;   
Werneke et al. 2006). 
  Pharmacogenetic research has only recently 
begun to identify genetic markers that may predict 
response to antidepressant treatment (Lin and 
Chen 2008; Drago et al. 2009; Ising et al. 2009; 
Schosser and Kasper 2009; Uher et al. 2009b, 2010; 
Kato and Serretti 2010). These markers may facili-
tate the prediction of adverse events such as SD dur-
ing antidepressant treatment (Bishop et al. 2009). It 
has been hypothesised that the development of SD 
during treatment with serotonergic antidepressants 
is moderated by variations in the serotonin trans-
porter gene (  SLC6A4  ), which encodes the serotonin 
transporter protein (5-HTT; Bishop et al. 2009). 
The polymorphism in   SLC6A4   which has been most 
studied for association with SD to date is the 
  5-HTTLPR  , an insertion/deletion of 44 base pairs 
(bp) within the promoter region. An association has 
been reported between   5-HTTLPR   genotype and 
response to antidepressant treatment, in which car-
riers of the long allele show a better response than 
short allele homozygotes (Serretti et al. 2007; Huezo-
Diaz et al. 2009). Long allele homozygotes have also 
been shown to experience more SD during SSRI 
treatment for depression (Bishop et al. 2009). 
Furthermore, an association has been found between 
the short allele and premature ejaculation (Ozbek 
et al. 2009), whereas Janssen et al. (2009) reported 
in s-carriers with premature ejaculation longer ejac-
ulation times compared to long allele homozygotes. 530          J. Strohmaier et al.
mild, moderate, severe). Each study participant was 
asked to complete the ASEC before commencing the 
study medication, and then weekly for 12 weeks. The 
ASEC item 12 was selected as the main outcome 
measure due to its weekly application and low rate 
of missing data. The UKU Side Effects Rating Scale 
(UKU) is a comprehensive semi-structured inter-
view which assesses psychic and physical adverse 
reactions to psychotropic drugs (Lingjaerde et al. 
1987). Five of the 48 UKU items (desire, erection, 
ejaculation, vaginal lubrication, orgasm) enquire 
speciﬁ  cally about SD according to a four-point scale. 
The Sexual Functioning Questionnaire (SFQ; Smith 
et al. 2002) is a 38-item self-rating questionnaire that 
measures current sexual functioning across various 
domains (libido, arousal, erection, ejaculation, vagi-
nal lubrication, orgasm) according to a two-point 
scale. Higher scores indicate greater sexual dysfunc-
tion in the respective domain. In GENDEP, the 
  UKU   and the   SFQ   were administered at baseline 
and at study weeks 8 and 12 (Uher et al. 2009a).     
  Genotyping and quality control 
  Blood samples were collected in ethylenediamine 
tetra-acetic acid and frozen. DNA was extracted using 
a standard procedure (Freeman et al. 2003). Short 
and long alleles of the   5-HTTLPR   were determined 
using polymerase chain reaction (PCR) with a previ-
ously described method (de Bakker et al. 2005).     
  Statistical analyses 
  A repeated measures ANOVA was used to compare 
differences in the main outcome measure (  ASEC   
item 12) at baseline and all subsequent study weeks 
between drop-outs and subjects who completed the 
entire protocol. In this analysis, study week was a 
within-subject factor and drop-out vs. non-drop-out 
and sex were between-subject factors. All subsequent 
ANOVAs were computed with study week as a with-
in-subject factor and sex as a between-subject factor. 
For the inﬂ  uence of study medication, a repeated 
measures ANOVA was computed with study medi-
cation as a between-subject factor. In a subsequent 
step, change in depressive symptoms during the 
course of treatment (difference in MADRS sum-
mary scores and depressive symptom dimensions 
between baseline and week 12), age, and genotype 
status at the   5-HTTLPR   locus (s/s vs. s/l vs. l/l) were 
added to the model as further predictors. 
  To limit the number of statistical analyses, only the 
genetic association between the 5-HTTLPR and the 
main outcome measure (ASEC item 12) was tested. 
A further reason for focusing the genetic association 
analysis on ASEC item 12 was the high rate of missing 
gendep.iop.kcl.ac.uk/results.php). The study was 
partly randomised, i.e. patients were only randomised 
to treatment in the absence of any contraindication 
to either of the two study drugs. All subjects met 
ICD-10/DSM-IV criteria for a major depressive epi-
sode. Patients were treated with nortriptyline or esci-
talopram for a period of 12 weeks. Escitalopram was 
initiated at a dose of 10 mg daily, and this was 
increased to a target dose of 15 mg daily within the 
ﬁ  rst 2 weeks. The dose could be further increased to 
20 mg daily, or up to 30 mg when there was clinical 
agreement that a higher dose was indicated. Nortri-
ptyline was initiated at 50 mg daily and titrated to a 
target dose of 100 mg daily within the ﬁ  rst 2 weeks. 
The dose could be increased to 150 mg daily, or up 
to 200 mg when there was clinical agreement that a 
higher dose was indicated. Adjunct psychotropic 
medication was not allowed, with the exception of 
occasional hypnotics. Compliance was monitored 
weekly by self-reported pill count, and antidepres-
sant plasma levels were measured at week 8. Written 
informed consent was obtained from all participants 
prior to inclusion. A detailed description of the 
GENDEP sample and treatment outcomes is pro-
vided elsewhere (Uher et al. 2009c). Only subjects 
who had been randomly allocated to treatment were 
included in the present study to exclude possible 
confounding between pre-treatment SD and treat-
ment allocation. The ﬁ  nal sample included 176 males 
(mean age 41.7      12.5 years) and 318 females 
(mean age 42.4      11.0 years). Forty-six males and 
70 females discontinued the study medication before 
week 12 and were thus considered study drop-outs.     
  Measures 
  Depression severity was measured weekly using three 
established scales: (i) the clinician-rated 10-item 
Montgomery  –  Asberg Depression Rating Scale 
(MADRS); (ii) the clinician rated 17-item Hamilton 
Rating Scale for Depression (HRSD-17); and (iii) 
the self-report 21-item Beck Depression Inventory 
(BDI). The MADRS provides the most accurate and 
internally valid reﬂ   ection of depression severity 
(Uher et al. 2008). Joint factor analysis of the items 
of all three depression scales revealed three depressive 
symptom dimensions that provide a more detailed 
description of depression severity: (i) observed mood 
and anxiety, (ii) cognitive symptoms, and (iii) 
neurovegetative symptoms (Uher et al. 2008). 
  Sexual function was measured weekly with the 
Antidepressant Side-Effect Checklist (ASEC; Uher 
et al. 2009a). The ASEC is a self-report instrument 
that was designed to measure 21 adverse reactions 
to antidepressants. Item 12 rates problems with sex-
ual function according to a four-point scale (absent, Sexual  dysfunction,  antidepressants  and  the  5-HTTLPR        531
decrease over time was observed (main effect Time 
  F    4.477;158        2.037,   P        0.08). Separate analyses for 
males and females revealed a signiﬁ  cant main effect 
for Time in females only (  F    5.437;98        2.963,   P        0.01), 
with not even a trend being identiﬁ   ed in males 
(  F    2.466;60        0.908,   P        0.423). The highest SD rates 
were reported at baseline, i.e. when the subjects were 
still medication free. On a descriptive level, this trend 
was more pronounced in females than in males, with 
20.3% of females reporting severe SD at baseline and 
only 5.8% of males (see Discussion). There was no 
evidence that study medication inﬂ  uenced the overall 
severity or the time course of SD (main effect Medica-
tion   F    1;156        0.027,   P        0.869, interaction Time            
Medication   F    4.491;156        0.226,   P        0.939; Figure 1). 
  An analysis was then performed to investigate 
whether the change in depressive symptoms (i.e. the 
difference between MADRS summary scores at base-
line and at week 12) had any impact on SD. The 
ANOVA revealed a signiﬁ   cant interaction effect of 
Time      MADRS (  F    4.780;154        5.016,   P        0.001). This 
effect was controlled for medication and sex, although 
it was virtually identical without controlling for these 
variables. To provide a graphical illustration (Figure 2), 
a median split was performed for the MADRS differ-
ence. Subjects with a more pronounced decrease in 
depressive symptoms over time also reported a more 
pronounced reduction in SD (Time      MADRS 
Median Split   F    4.665;157        3.544,   P        0.004). Further-
more, all available information on depression was used 
to explore the impact on SD of the change in depres-
sive symptoms as indexed by the following three 
dimensions: (i) observed mood and anxiety, (ii) cogni-
tive symptoms, and (iii) neurovegetative symptoms. 
The decrease in depressive symptoms between base-
line and week 12 was most pronounced for observed 
mood and anxiety symptoms (mean difference      1.69, 
SD      0.87), followed by cognitive symptoms (mean 
difference      1.42, SD      0.87). The smallest decrease 
was observed for neurovegetative symptoms (mean 
difference      1.13, SD      0.91). All differences were 
signiﬁ  cant (  P        0.001). In a supplementary analysis, 
the ANOVA was repeated using the differences in the 
scores of these three depressive symptom dimensions 
data for the UKU and SFQ, which resulted in very 
low statistical power. 
  For the ﬁ  ve individual UKU items and the SFQ 
subscales, similar repeated measures ANOVAs were 
performed as those carried out for the main outcome 
measure (ASEC item 12). Study week was entered 
as a within-subject factor and sex as a between-sub-
ject factor. The stepwise inclusion of study medica-
tion, age, and the change in depressive symptoms 
during the course of treatment (difference between 
MADRS summary score at baseline and week 12) 
were considered as further predictors. Due to a high 
rate of missing data for the SFQ, this analysis was 
restricted to data from baseline and study week 12. 
  All analyses were performed in SPSS version 17.0. 
Greenhouse  –  Geisser corrections were applied where 
appropriate, and only adjusted results are reported.       
  Results   
  Genotyping 
  Genotype data were available for 473 subjects. Gen-
otype frequencies for the   5-HTTLPR   variant were 
192 l/l (0.41), 211 l/s (0.45), and 70 s/s (0.14). These 
are consistent with previously reported frequencies, 
and did not deviate signiﬁ  cantly from Hardy  –  Wein-
berg equilibrium (  P        0.33).     
  Results obtained from the various sexual function 
rating scales 
    Antidepressant Side-Effect Checklist.   Subjects who 
dropped out of the study did not differ signiﬁ  cantly 
from those who completed the protocol in terms of 
the main outcome measure (ASEC item 12; main 
effect Group   F    1;156        0.064,   P        0.801; interaction 
Sex      Group   F    1;156        0.112,   P        0.738). The data 
of study drop-outs were therefore included in the 
analyses. The drop-out rate was linear, with around 
10% of running subjects dropping out each week. 
      In both treatment groups, the majority of patients 
reported no, or only mild, SD according to ASEC item 
12 (see Table I). Furthermore, a trend towards a 
    Table I. Percentage of reported SD according to   ASEC   item 12.   
SD Baseline SW 1 SW 2 SW 3 SW 4 SW 5 SW 6 SW 7 SW 8 SW 9 SW 10 SW 11 SW 12
Males None 53.8 61.5 61.2 62 64 59.1 59.8 60.3 58.9 58.8 62.1 65.6 65
Mild 19.9 17.3 18.4 18.7 20.9 21.9 20.5 22.4 21.4 21.6 21.1 17.8 19
Moderate 20.5 15.4 15.1 14.7 10.8 13.1 13.4 10.3 13.4 13.7 9.5 11.1 12
Severe 5.8 5.8 5.3 4.7 4.3 5.8 6.3 6.9 6.3 5.9 7.4 5.6 4
Females None 52.6 66.5 68.4 69.8 70.5 70.7 62.4 69.2 68.5 66.7 67.8 64.2 66.1
Mild 11.7 10.2 9.6 10.1 8.1 7.9 11.4 7.1 9.3 10.4 8.7 11.4 9.8
Moderate 15.5 10.2 7.4 7.1 7.8 7.5 13.1 9.8 12 11.5 11.5 13.6 12
Severe 20.3 13 14.7 13.1 13.6 13.8 13.1 13.8 10.2 11.5 12 10.8 12
SW, study week.532          J. Strohmaier et al.
  The ﬁ   nal analysis tested for an association 
between   5-HTTLPR   genotype and SD. No main 
effect was detected for Genotype (  F    2;142        0.057, 
  P        0.945). Similarly, no main effect was detected 
for any of the following interactions: Time      Gen-
otype (  F    9.726;142        0.812,   P         0.614); Medica-
tion      Genotype (  F    2;142        0.293,   P        0.747); or 
three-way Time      Medication      Genotype 
(  F    9.726;142        0.872,   P        0.557). To test for a pos-
sible interaction between age and genotype on 
reported SD, the continuous variable age was con-
verted into a categorical variable by performing a 
median split (Median Split     42 vs.     42). The sub-
sequent ANOVA revealed a signiﬁ  cant interaction 
for Age Median Split      Genotype (  F    2;131        3.559, 
  P        0.031), with younger s/s subjects reporting less 
SD than older s/s subjects (see Figure 3). Again, 
this effect was not signiﬁ  cantly modiﬁ  ed by medica-
tion (Medication      Age Median Split      Genotype 
F  2;131        0.004,   P        0.996).     
  UKU Side Effects Rating Scale 
  Table II shows the frequency of SD for each UKU 
item. Desire dysfunction decreased signiﬁ  cantly over 
time (main effect Time   F    1.888;211        24.219, 
  P        0.001). Women reported more severe desire dys-
function than men (main effect Sex   F    1;211        10.100, 
  P        0.002). This gender effect did not change over 
time (Time      Sex   F    1.888;211        0.048,   P        0.947). 
The decrease over time showed a trend towards 
being more pronounced in the escitalopram group 
(interaction Time      Medication   F    1.896;209        2.746, 
  P        0.068). The change in depressive symptoms had 
a signiﬁ  cant impact on desire dysfunction (interac-
tion Time     MADRS   F    1.909;205        4.691,   P        0.011). 
Subjects with a more pronounced decrease in depres-
sive symptoms also reported a more pronounced 
between baseline and week 12 rather than the differ-
ence in the MADRS score. The impact on SD of the 
change in depressive symptoms was most pronounced 
for the cognitive (Time      Cognitive Symptoms   
F    4.647;155        4.305,   P        0.001,   η    ²        0.027) and neu-
rovegetative symptoms (Time      Neurovegetative 
Symptoms   F    4.568;155        4.150,   P        0.001,   η    ²        0.026). 
The smallest impact on SD was observed for change 
in mood and anxiety symptoms (Time      Observed 
Mood and Anxiety Symptoms   F     4.630;155        3.541, 
  P        0.005,   η    ²        0.022). 
  Tests were then performed to assess the impact of 
age on SD. A trend towards a main effect for Age 
was observed (  F    1;153        3.039,   P        0.083), with older 
age being positively correlated with SD score. 
   
Figure 1.         Time course of reported sexual dysfunction (ASEC item 
12) over the 12-week study period for escitalopram and 
nortriptyline.   
   
Figure 3.         Interaction effect of the   5-HTTLPR   genotype (s/s, s/l, 
l/l) and age on reported sexual dysfunction (ASEC item 12).   
   
Figure 2.         Time course of reported sexual dysfunction (  ASEC   item 
12) over the 12-week study period according to the change in 
MADRS (Montgomery  –  Asberg Depression Rating Scale) in 
subjects with scores     18 points and     18 points.   Sexual  dysfunction,  antidepressants  and  the  5-HTTLPR        533
Erectile dysfunction was more common in subjects 
who showed a less pronounced decrease in depressive 
symptoms (main effect MADRS   F     1;63        4.396, 
  P        0.040), and in subjects who were older (main 
effect Age  F    1;62        4.274,   P        0.043). Both effects were 
independent of time (interaction Time      MADRS   
F    1.629;63        0.468,   P        0.588; interaction Time      Age   
F    1.625;62        0.194,   P        0.778). Ejaculation dysfunction 
showed a trend towards a decrease over time (main 
effect Time  F    1.832;63        3.120,   P        0.052), and no asso-
ciation was found with study medication, change in 
depressive symptoms, or age. For vaginal lubrication 
dysfunction, all possible effects were non-signiﬁ  cant. 
  Orgasmic dysfunction showed a trend towards a 
decrease over time (main effect Time  F    1.497;151       2.856, 
  P        0.075). Women reported more severe orgasmic 
dysfunction than men (main effect Sex F  1;151        3.490, 
  P        0.064). This trend did not reach signiﬁ  cance and 
did not change over time (interaction Time      Sex 
  F    1.497;151        0.034,   P        0.930). Subjects with a more 
pronounced decrease in depressive symptoms over 
time also reported a more pronounced reduction in 
orgasmic dysfunction (interaction Time      MADRS   
F    1.522;146        4.061,   P        0.028). No association was 
found with study medication or age.     
  Sexual Functioning Questionnaire 
  Table III shows the frequency of SD for each of 
the SFQ subscales. Desire dysfunction signiﬁ  cantly 
decreased over time (main effect Time  F    1.000;52       7.028, 
  P        0.011). Women reported more severe desire dys-
function than men (main effect Sex F  1;52        4.239, 
  P        0.045). This difference between women and men 
did not change over time (interaction Time      Sex   
reduction in desire dysfunction. Older subjects 
reported more severe desire dysfunction (main effect 
Age   F    1;204        5.248,   P        0.023). 
  Erectile dysfunction did not change over time, and 
no association with study medication was found. 
    Table III. Mean and standard deviation of reported SD according to the   SFQ   subscales.    
Baseline SW 8 SW 12
Desire Males Mean 1.82 1.41 1.20
Standard deviation 1.59 1.67 1.56
Females Mean 3.18 2.06 2.63
Standard deviation 1.89 1.97 2.07
Arousal Males Mean 2.02 1.6 1.35
Standard deviation 1.44 1.52 1.33
Females Mean 2.94 2.19 2.28
Standard deviation 1.46 1.57 1.57
Erection Males Mean 1.80 1.49 1.26
Standard deviation 1.77 1.95 1.69
Ejaculation Males Mean 0.6 0.25 0.45
Standard deviation 0.9 0.55 0.77
Lubrication Females Mean 2.85 2.48 2.41
Standard deviation 1.35 1.46 1.47
Orgasm Males Mean 1.23 1.16 0.68
Standard deviation 1.06 1.25 1.09
Females Mean 2.57 2.0 2.36
Standard deviation 1.67 1.48 1.55
      SW, study week.     
    Table II. Percentage of reported SD according to the   UKU   
items.    
Baseline SW 8 SW 12
Desire Males None 40.4 58.3 67
Mild 22.3 22.2 16
Moderate 26.5 12 13
Severe 10.8 7.4 4
Females None 29.6 48 49.4
Mild 16.4 18.1 20.8
Moderate 21.8 17.2 14.3
Severe 32.1 16.7 15.5
Erection Males None 86.4 88.5 86.7
Mild 7.5 6.3 7.8
Moderate 4.1 3.1 5.6
Severe 2 2.1 0
Ejaculation Males None 92.5 85.7 87.9
Mild 5.5 2.2 5.5
Moderate 2.1 7.7 6.6
Severe 0 4.4 0
Lubrication Females None 90.6 92.6 93.5
Mild 3 4 2.9
Moderate 2.6 1.1 1.4
Severe 3.9 2.3 2.2
Orgasm Males None 88.5 86 90.5
Mild 5.8 9.3 8.3
Moderate 4.3 1.2 0
Severe 1.4 3.5 1.2
Females None 77.4 84.1 84.1
Mild 6.3 6.5 6.5
Moderate 5 2.4 2.9
Severe 11.3 7.1 6.5
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nortriptyline group reported SD at week 8; and 14.9% 
in the escitalopram group and 19.7% in the nortrip-
tyline group reported SD at week 12. 
  A supplementary analysis of the two more in-depth 
measures (UKU and SFQ) indicated that lack of 
desire was the most prominent SD in both men and 
women. This decreased over time, and escitalopram 
may have had a more positive effect than nortrip-
tyline. Desire and orgasmic dysfunction were more 
frequent and severe in women than in men. Sexual 
difﬁ   culties in the other phases of the sexual cycle 
showed no change, or only a slight decrease, over 
time. This ﬁ  nding is plausible, since previous reports 
have suggested that SSRIs and TCAs cause reduced 
sexual desire and orgasmic dysfunction (Clayton 
et al. 2006a; Corona et al. 2009; Rosen et al. 1999; 
Serretti and Chiesa 2009; Werneke et al. 2006); how-
ever, it could also be due to the depressive disorder. 
Lack of sexual desire and orgasmic dysfunction are 
also more prevalent in women than in men in the 
general population (Laumann et al. 1999). 
  The SD rates in the present prospective and ran-
domised sample are substantially lower than those 
found in two previous studies by Clayton et al. 
(2006b, 2007) which reported rates of 34 to 48.7% 
following eight weeks treatment with escitalopram. In 
comparison to the present study, the above reports 
had narrower inclusion criteria. Clayton et al. (2006b) 
only included subjects with (self-reported) normal 
sexual functioning at baseline, who had agreed to 
report any changes in sexual functioning, and who 
reported that they were sexually active at least once 
every 2 weeks. The authors excluded subjects with 
pre-existing SD, anorexia nervosa, bulimia, seizure 
disorders, brain injury, panic disorder, obsessive-
compulsive disorder, post-traumatic stress disorder, 
acute stress disorder or a history of attempted suicide 
within the previous 6 months. The impact of these 
differences in study protocol on reported SD rates is 
unknown. It is plausible, however, that the patients  ’   
knowledge of the explicit aim to assess SD may have 
enhanced their awareness of such symptoms. 
  The results of a multinational study that compared 
escitalopram with paroxetine are consistent with 
those of the present study (Baldwin et al. 2006). In 
both treatment groups, reported SD declined over 
the course of treatment, and differences between 
treatment groups were not signiﬁ  cant,  although 
reported SD rates were higher than in the present 
study. Again, the inclusion criteria were more nar-
rowly deﬁ  ned. The authors argued that the decline 
may have been due to the dropping-out of patients 
with more severe SD (Baldwin et al. 2006). However, 
drop-outs in the present study did not differ subs-
tantially from subjects who completed the protocol in 
terms of reported SD. Moreover, a lower prevalence 
F    1.000;52        0.257,   P        0.614). The decrease in desire 
dysfunction was marginally more pronounced in the 
escitalopram group (interaction Time      Medication 
  F    1.000;50        2.561,   P        0.116). Subjects with a more 
pronounced decrease in depressive symptoms also 
reported less severe desire dysfunction (main effect 
MADRS   F    1;48        11.259,   P        0.002). Older subjects 
reported more severe desire dysfunction than younger 
subjects (main effect Age (  F    1;47        6.421,   P        0.015). 
  Arousal dysfunction signiﬁ  cantly decreased over 
time (main effect Time  F    1.000;51       12.641,  P       0.001). 
Subjects with a more pronounced decrease in depres-
sive symptoms over time also reported a more pro-
nounced reduction in arousal dysfunction (interaction 
Time      MADRS   F    1.000;47        7.450,   P        0.009). No 
signiﬁ  cant effects were found for study medication, 
sex, or age. 
  Erectile dysfunction decreased over time (main 
effect Time   F    1.000;21        5.469,   P        0.029) and older 
subjects reported more severe erectile dysfunction 
(  F    1;18       6.157,  P       0.023). No inﬂ  uence was observed 
for study medication or change in depressive symp-
toms. No signiﬁ  cant effects were observed for ejacula-
tion dysfunction or vaginal lubrication dysfunction. 
  Orgasmic dysfunction decreased over time in 
men but not in women (interaction Time      Sex 
  F    1.000;42        6.402,   P        0.015), and men reported less 
severe orgasmic dysfunction than women (main 
effect Sex F  1;42        14.680,   P        0.001). All other SFQ 
main and interaction effects failed to reach statistical 
signiﬁ  cance.       
  Discussion 
  The primary aim of the present study was to inves-
tigate the association between the   5-HTTLPR   and 
SD during treatment with antidepressants with 
contrasting modes of action within the context of 
the large pharmacogenetic GENDEP study. We 
hypothesised that there would be a signiﬁ  cant asso-
ciation with SD during treatment with the SSRI 
escitalopram but not during treatment with the 
TCA nortriptyline. 
  Our most prominent ﬁ  nding was that the majority 
of subjects reported no, or only mild, SD despite 
explicit and frequent assessment. The highest rates of 
SD were reported at baseline, when subjects were still 
medication-free, particularly in females. Over the 
course of treatment, reported SD showed a slight 
decrease. After 12 weeks of treatment, 16% of males 
and 24% of females reported moderate or severe SD. 
The decrease over time was only statistically signiﬁ  cant 
in females, and was based on a pronounced decrease 
in reported SD within the ﬁ  rst study week, i.e. between 
baseline and week 1. Of those subjects with no SD at 
baseline, 15.1% in the escitalopram and 16.4% in the Sexual  dysfunction,  antidepressants  and  the  5-HTTLPR        535
risk factor for SD (Phanjoo 2000; Derogatis and 
Burnett 2008; Corona et al. 2010). 
  Finally, we found no inﬂ  uence of   5-HTTLPR   gen-
otype on reported SD on average, over the time 
course of treatment, or in interaction with the study 
medication. However, our data suggest a possible 
inﬂ   uence of age on the association between the 
  5-HTTLPR   genotype and reported SD. The inﬂ  u-
ence of age on sexual function may be more pro-
nounced in s/s subjects than in patients with the 
genotype s/l or l/l. One previous report found that 
the s/s genotype was associated with less SD than the 
l/l genotype during SSRI treatment, although this 
study did not report any inﬂ  uence of age (Bishop et 
al. 2009). However, the age distribution of the Bishop 
et al. sample (2009) differed signiﬁ  cantly (  t        11.70, 
  P        0.01) from that of the present study. In the 
present sample, subjects with genotype data were 
between 19 and 72 years of age, and the mean age 
was 42.11 years. The study by Bishop et al. (2009) 
included relatively young patients of between 18 and 
40 years of age (mean of 29.2 years) in order to 
minimise the confounding effect of age on the pres-
ence of SD. The lower proportion of older subjects 
may explain why Bishop et al. (2009) found no 
inﬂ   uence of age on the association between the 
  5-HTTLPR   genotype and reported SD. 
  The present study met several of the methodolog-
ical quality criteria for the evaluation of antidepres-
sant related SD (Montgomery et al. 2002; Schweitzer 
et al. 2009). These included: (i) a randomised and 
prospective design; (ii) comparisons between differ-
ent treatments; (iii) a baseline assessment; (iv) the 
use of deﬁ  ned diagnostic criteria for depression; (v) 
the application of reliable and validated rating scales 
for the assessment of SD in men and women; (vi) 
direct assessment of depression and sexual function 
before and during treatment; and (vii) consideration 
of the possible effects of degree of remission and 
gender on the outcome variables. However, the study 
had several limitations. Firstly, we did not control for 
comorbid illness or concomitant medications that 
might affect normal sexual function. A previous 
study, which involved neither random assignment 
nor baseline control, controlled for these factors and 
compared several different antidepressants. This 
found the highest prevalence rates for SD during 
treatment with the SSRI citalopram (Clayton et al. 
2002). We did, however, exclude individuals who had 
a contraindication to both study medications, who 
were currently being treated for a somatic disease 
using potentially depressogenic medications, or who 
were using other psychotropic medications, with the 
exception of the occasional use of hypnotics. A 
second very important limitation is that patients 
of ejaculatory problems has been reported for 
escitalopram compared with other SSRIs following 
8 weeks of treatment (Hirschfeld and Vornik 
2004). A small study (  N        47) reported a reduction 
in SD in the majority of subjects who switched from 
other SSRIs or serotonin-norepinephrine reuptake 
inhibitors to escitalopram (Ashton et al. 2005). Esci-
talopram is associated with lower rates of treatment-
withdrawal, and fewer discontinuation symptoms, 
than paroxetine (Baldwin et al. 2006, 2007). 
  It is important to acknowledge that SD is wide-
spread in the general population. Estimates of 11% 
for frequent or severe SD and 69% for infrequent or 
mild difﬁ  culties have been reported. Men predomi-
nantly report ejaculatory problems, with overall rates 
of between 10 and 20%, whereas lack of sexual desire 
is most prevalent in women, with rates of between 
20 and 25%. Women also report higher rates of 
orgasm dysfunction than men (Laumann 
et al. 1999; Montgomery et al. 2002; Derogatis and 
Burnett 2008; Laumann et al. 2009; Christensen 
et al. 2010). In the present study, the SD rates 
reported after 12 weeks of antidepressant treatment 
(16% in males and 24% in females) only slightly 
exceed the SD rates in the general population. 
  Given the rather low rates of reported SD, it is not 
surprising that we failed to detect a major inﬂ  uence 
of study medication or the   5-HTTLPR   on reported 
SD or its time course in the analysis of the main 
outcome measure. No signiﬁ   cant differences in 
reported SD were observed between patients receiv-
ing escitalopram and those receiving nortriptyline. 
  A more pronounced decrease in reported SD was 
found in subjects whose depression improved sub-
stantially. This is consistent with previous ﬁ  ndings 
for escitalopram, duloxetine, nortriptyline, and ser-
traline, and suggests that SD is inﬂ  uenced by the 
remission of depression and may not be a side-effect 
of antidepressant treatment (Lanza di Scalea et al. 
2009). The effect was similar for the three depressive 
symptom dimensions   “  observed mood and anxiety  ”  , 
  “  cognitive symptoms  ”  , and   “  neurovegetative symp-
toms  ”  . This may be due to the high correlation 
between the changes in depressive symptoms over 
time across the three dimensions. Observed mood 
and anxiety symptoms showed the most pronounced 
improvement and neurovegetative symptoms the 
least. The effects of study medication on the improve-
ments in each of these three symptom dimensions 
have been described and discussed elsewhere (Uher 
et al. 2009c). 
  We also observed an inﬂ  uence of age on reported 
SD. Younger subjects reported less SD than older 
subjects particularly for desire and erection difﬁ  culties. 
This ﬁ  nding is plausible, since age is an established 536          J. Strohmaier et al.
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